{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:51Z","timestamp":1793159151215,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-024-06303-z","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T01:24:59Z","timestamp":1740705899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"John","family":"Perna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Trop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Palitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Bosshardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Vantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boadie W.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali J.","family":"Zarrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"5","key":"6303_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020;177(5):391\u2013410.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"6303_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2021.2022254","volume":"55","author":"A Hadar","year":"2023","unstructured":"Hadar A, David J, Shalit N, Roseman L, Gross R, Sessa B, et al. The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. J Psychoactive Drugs. 2023;55(1):1\u201310.","journal-title":"J Psychoactive Drugs"},{"key":"6303_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83\u2013102.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"6303_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/2045125316638008","volume":"6","author":"RG dos Santos","year":"2016","unstructured":"dos Santos RG, Os\u00f3rio FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology. 2016;6(3):193\u2013213.","journal-title":"Ther Adv Psychopharmacol"},{"key":"6303_CR5","doi-asserted-by":"publisher","first-page":"780696","DOI":"10.3389\/fpsyt.2021.780696","volume":"12","author":"R Matzopoulos","year":"2021","unstructured":"Matzopoulos R, Morlock R, Morlock A, Lerer B, Lerer L. Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes. Front Psychiatry. 2021;12:780696.","journal-title":"Front Psychiatry."},{"issue":"5","key":"6303_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jadohealth.2024.01.027","volume":"74","author":"R Farah","year":"2024","unstructured":"Farah R, Kerns AF, Murray AC, Holstege CP. Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade. J Adolesc Health. 2024;74(5):1053\u20136.","journal-title":"J Adolesc Health."},{"key":"6303_CR7","first-page":"269881124126575","volume":"31","author":"R Palitsky","year":"2024","unstructured":"Palitsky R, Kaplan DM, Perna J, Bosshardt Z, Maples-Keller JL, Levin-Aspenson HF, et al. A framework for assessment of adverse events occurring in psychedelic-assisted therapies. J Psychopharmacol. 2024;31:2698811241265756.","journal-title":"J Psychopharmacol."},{"issue":"6","key":"6303_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol."},{"issue":"5","key":"6303_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0022167817711304","volume":"57","author":"J Phelps","year":"2017","unstructured":"Phelps J. Developing Guidelines and Competencies for the Training of Psychedelic Therapists. J Humanist Psychol. 2017;57(5):450\u201387.","journal-title":"J Humanist Psychol."},{"key":"6303_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/7854_2021_266","volume":"56","author":"J Phelps","year":"2022","unstructured":"Phelps J, Henry J. Foundations for Training Psychedelic Therapists. Curr Top Behav Neurosci. 2022;56:93\u2013109.","journal-title":"Curr Top Behav Neurosci"},{"key":"6303_CR11","doi-asserted-by":"publisher","first-page":"586682","DOI":"10.3389\/fpsyt.2021.586682","volume":"12","author":"SJ Tai","year":"2021","unstructured":"Tai SJ, Nielson EM, Lennard-Jones M, Johanna Ajantaival RL, Winzer R, Richards WA, et al. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. Front Psychiatry. 2021;12:586682.","journal-title":"Front Psychiatry."},{"issue":"2","key":"6303_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","volume":"29","author":"B Eisner","year":"1997","unstructured":"Eisner B. Set, setting, and matrix. J Psychoactive Drugs. 1997;29(2):213\u20136.","journal-title":"J Psychoactive Drugs"},{"issue":"326","key":"6303_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","volume":"1","author":"O Simonsson","year":"2023","unstructured":"Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. J Affect Disord. 2023;1(326):105\u201310.","journal-title":"J Affect Disord"},{"issue":"1","key":"6303_CR14","doi-asserted-by":"publisher","first-page":"15998","DOI":"10.1038\/s41598-023-41145-x","volume":"13","author":"R Bremler","year":"2023","unstructured":"Bremler R, Katati N, Shergill P, Erritzoe D, Carhart-Harris RL. Case analysis of long-term negative psychological responses to psychedelics. Sci Rep. 2023;13(1):15998.","journal-title":"Sci Rep"},{"key":"6303_CR15","doi-asserted-by":"crossref","unstructured":"Gard DE, Pleet MM, Bradley ER, Penn AD, Gallenstein ML, Riley LS, DellaCrosse M, Garfinkle EM, Michalak EE, Woolley JD. Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies. J Affect Disord Rep. 2021;6:100240.","DOI":"10.1016\/j.jadr.2021.100240"},{"issue":"1","key":"6303_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/02698811221131997","volume":"37","author":"E Morton","year":"2023","unstructured":"Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of \u201cmagic mushroom\u201d consumption. J Psychopharmacol. 2023;37(1):49\u201360.","journal-title":"J Psychopharmacol."},{"issue":"12","key":"6303_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1176\/appi.ajp.22010073","volume":"179","author":"G Barber","year":"2022","unstructured":"Barber G, Nemeroff CB, Siegel S. A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. AJP. 2022;179(12):892\u20136.","journal-title":"AJP"},{"issue":"2","key":"6303_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday JS, Davis AK, Mitzkovitz CM, Bloesch EK, Davoli CC. Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacol Transl Sci. 2021;4(2):424\u201335.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"6303_CR19","doi-asserted-by":"publisher","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"E Studerus","year":"2012","unstructured":"Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. PLoS ONE. 2012;7(2):e30800.","journal-title":"PLoS ONE."},{"issue":"117","key":"6303_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"15","author":"FS Barrett","year":"2017","unstructured":"Barrett FS, Johnson MW, Griffiths RR. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers Individ Dif. 2017;15(117):155\u201360.","journal-title":"Pers Individ Dif"},{"issue":"5","key":"6303_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"S McNamee","year":"2023","unstructured":"McNamee S, Devenot N, Buisson M. Studying Harms Is Key to Improving Psychedelic-Assisted Therapy\u2014Participants Call for Changes to Research Landscape. JAMA Psychiat. 2023;80(5):411.","journal-title":"JAMA Psychiat"},{"key":"6303_CR22","doi-asserted-by":"publisher","first-page":"1125780","DOI":"10.3389\/fpsyg.2023.1125780","volume":"14","author":"P Plesa","year":"2023","unstructured":"Plesa P, Petranker R. Psychedelics and neonihilism: connectedness in a meaningless world. Front Psychol. 2023;14:1125780.","journal-title":"Front Psychol"},{"issue":"4","key":"6303_CR23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/1468-5922.12949","volume":"68","author":"HM Osterhold","year":"2023","unstructured":"Osterhold HM, Fernandes-Osterhold G. Chasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance. J Anal Psychol. 2023;68(4):638\u201364.","journal-title":"J Anal Psychol"},{"key":"6303_CR24","doi-asserted-by":"crossref","unstructured":"Lindahl JR, Britton WB, Cooper DJ. Fear and Terror in Buddhist Meditation: A Cognitive Model for Meditation-Related Changes in Arousal and Affect. JCH. 2022 Dec 24 [cited 2024 Aug 2];7(1\u20132). Available from: https:\/\/journal.equinoxpub.com\/JCH\/article\/view\/22807.","DOI":"10.1558\/jch.22807"},{"issue":"6","key":"6303_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1037\/a0030382","volume":"103","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Landau MJ, Kay AC, Rothschild ZK. Collectivism and the meaning of suffering. J Pers Soc Psychol. 2012;103(6):1023\u201339.","journal-title":"J Pers Soc Psychol"},{"issue":"4","key":"6303_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jts5.46","volume":"3","author":"R Palitsky","year":"2019","unstructured":"Palitsky R, Sullivan D, Young IF, Dong S. Worldviews and the construal of suffering from depression. J Theo Soc Psychol. 2019;3(4):191\u2013208.","journal-title":"J Theo Soc Psychol"},{"key":"6303_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102997","volume":"87","author":"L Gashi","year":"2021","unstructured":"Gashi L, Sandberg S, Pedersen W. Making, \u201cbad trips\u201d good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy. 2021;87: 102997.","journal-title":"Int J Drug Policy"},{"key":"6303_CR28","unstructured":"Grof S, Grof C, editors. Spiritual emergency: when personal transformation becomes a crisis. 1st ed. Los Angeles: New York: Tarcher: Distributed by St. Martin\u2019s Press; 1989. p 250."},{"key":"6303_CR29","unstructured":"Jules Evans. Psychedelic Cults [Internet]. Ecstatic Integration. 2024 [cited 2024 Oct 29]. Available from: https:\/\/www.ecstaticintegration.org\/p\/psychedelic-cults."},{"issue":"1","key":"6303_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/0959353597071004","volume":"7","author":"JJ Freyd II","year":"1997","unstructured":"Freyd JJ II. Violations of Power, Adaptive Blindness and Betrayal Trauma Theory. Fem Psychol. 1997;7(1):22\u201332.","journal-title":"Fem Psychol"},{"issue":"4","key":"6303_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hast.1602","volume":"54","author":"D Rosenbaum","year":"2024","unstructured":"Rosenbaum D, Hare C, Hapke E, Herman Y, Abbey SE, Sisti D, et al. Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit Analysis. Hastings Cent Rep. 2024;54(4):32\u201346.","journal-title":"Hastings Cent Rep"},{"issue":"2","key":"6303_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1021\/acsptsci.0c00198","volume":"4","author":"MW Johnson","year":"2021","unstructured":"Johnson MW. Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine. ACS Pharmacol Transl Sci. 2021;4(2):578\u201381.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"6303_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1037\/vio0000354","volume":"11","author":"JF Duron","year":"2021","unstructured":"Duron JF, Johnson L, Hoge GL, Postmus JL. Observing coercive control beyond intimate partner violence: Examining the perceptions of professionals about common tactics used in victimization. Psychol Violence. 2021;11(2):144\u201354.","journal-title":"Psychol Violence"},{"issue":"1","key":"6303_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1467-9744.2006.00805.x","volume":"42","author":"J Rindfleish","year":"2007","unstructured":"Rindfleish J. The \u201cdeath of the ego\u201d in east-meets-west spirituality: diverse views from prominent authors. Zygon. 2007;42(1):65\u201376.","journal-title":"Zygon"},{"issue":"3","key":"6303_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1525\/nr.2018.21.3.47","volume":"21","author":"E Davis","year":"2018","unstructured":"Davis E. The Psychedelic Book of the Dead. Nova Religio. 2018;21(3):47\u201373.","journal-title":"Nova Religio"},{"issue":"7","key":"6303_CR36","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamapsychiatry.2023.1554","volume":"80","author":"R Palitsky","year":"2023","unstructured":"Palitsky R, Kaplan DM, Peacock C, Zarrabi AJ, Maples-Keller JL, Grant GH, et al. Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies. JAMA Psychiat. 2023;80(7):743.","journal-title":"JAMA Psychiat"},{"issue":"16","key":"6303_CR37","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1056\/NEJMp2403872","volume":"391","author":"C Adrian","year":"2024","unstructured":"Adrian C. Taking Our Own Medicine. N Engl J Med. 2024;391(16):1472\u20133.","journal-title":"N Engl J Med"},{"key":"6303_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2024.2401982","volume":"13","author":"A Wilson-Poe","year":"2024","unstructured":"Wilson-Poe A, Hoffman K, Pertl K, Luoma J, Bazinet A, Stauffer C, et al. Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts. J Psychoactive Drugs. 2024;13:1\u20138.","journal-title":"J Psychoactive Drugs"},{"key":"6303_CR39","first-page":"1","volume":"2","author":"N Emmerich","year":"2023","unstructured":"Emmerich N, Humphries B. Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist\u2019s Training? Camb Q Healthc Ethics. 2023;2:1\u201310.","journal-title":"Camb Q Healthc Ethics"},{"key":"6303_CR40","first-page":"1","volume":"12","author":"D Villiger","year":"2024","unstructured":"Villiger D. Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited? Int Rev Psychiatry. 2024;12:1\u201310.","journal-title":"Int Rev Psychiatry"},{"issue":"5","key":"6303_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/archpsyc.1963.01720110051006","volume":"8","author":"S Cohen","year":"1963","unstructured":"Cohen S. Prolonged Adverse Reactions to Lysergic Acid Diethylamide. Arch Gen Psychiatry. 1963;8(5):475.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"6303_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1176\/ajp.121.3.238","volume":"121","author":"SH Rosenthal","year":"1964","unstructured":"Rosenthal SH. Persistent hallucinosis following repeated administration of hallucinogenic drugs. AJP. 1964;121(3):238\u201344.","journal-title":"AJP"},{"key":"6303_CR43","doi-asserted-by":"publisher","DOI":"10.4324\/9780203874318","volume-title":"A casebook of cognitive therapy for traumatic stress reactions","author":"N Grey","year":"2009","unstructured":"Grey N. A casebook of cognitive therapy for traumatic stress reactions. London: Routledge; 2009."},{"issue":"6193","key":"6303_CR44","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/bmj.2.6193.797-b","volume":"2","author":"NS Davies","year":"1979","unstructured":"Davies NS. Psychiatric symptoms and hallucinogenic compounds. BMJ. 1979;2(6193):797\u2013797.","journal-title":"BMJ"},{"key":"6303_CR45","doi-asserted-by":"publisher","unstructured":"Brown J. Ethical transgressions and boundary violations in ayahuasca healing contexts: a mixed methods study. 2020 [cited 2024 Oct 29]; Available from:\u00a0https:\/\/doi.org\/10.13140\/RG.2.2.25017.95845.","DOI":"10.13140\/RG.2.2.25017.95845"},{"issue":"3","key":"6303_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1176\/ajp.128.3.351","volume":"128","author":"DJ Muller","year":"1971","unstructured":"Muller DJ. ECT in LSD Psychosis: A Report of Three Cases. AJP. 1971;128(3):351\u20132.","journal-title":"AJP"},{"issue":"7676","key":"6303_CR47","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S0140-6736(70)90220-5","volume":"296","author":"Hatrick JohnA","year":"1970","unstructured":"JohnA Hatrick, Dewhurst K. Delayed psychosis due to L.S.D. The Lancet. 1970;296(7676):742\u20134.","journal-title":"The Lancet."},{"issue":"7","key":"6303_CR48","first-page":"29","volume":"1","author":"R Metzner","year":"1969","unstructured":"Metzner R. A note on the treatment of LSD psychosis. Behav Neuropsychiatry. 1969;1(7):29\u201332.","journal-title":"Behav Neuropsychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06303-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T01:59:37Z","timestamp":1740707977000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06303-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6303"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06303-z","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient signed a voluntary written informed consent form authorizing the publication. A copy is available if requested.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}